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• The worldwide growth of patients with end-stage kidney 
disease requiring renal replacement therapy (RRT) in the 
form of dialysis or transplantation is over 6% per annum 
(Grassmann et al. 2006). 
 
• The arteriovenous fistula is the ideal vascular access. A 
significant number of arteriovenous fistula (28 to 53%) 












(Adapted from Allon 2007) 
Study Aim 
 
To explore the role of blood markers and patient 
factors in the predication of maturation of 
arteriovenous fistula in patients who have 
undergone vascular access surgery at the Royal 




 Retrospective Study 
Setting/Location of study 
  Royal Infirmary of Edinburgh 
Intervention 
 Creation of Autologous Arteriovenous Fistulae 
Sample Size 
 300 patients undergoing fistula creation between 2006 and 2009 
Ethical Approval 
 Lothian Research Ethics Committee   
 Queen Margaret University Ethics Committee 
Lipid Profile 
• High Density 
Lipoprotein (HDL) 
• Triglyceride (TG) 




• Peripheral Vascular Diseases (PVD) 
• Diabetes Mellitus (DM) 
• Hypertension (HTN)  
• Basal Metabolic Index (BMI) 
• Dialysis 
• Smoking  
• Vein Size 
• Type of Arteriovenous Fistulae 
• Side of Arm 
Kidney Function 
• Glomerular Filtration Rate 
(GFR) 
• Serum Potassium (K+) 
• Serum Sodium (Na) 
• Serum Calcium (Ca) 
• Bicarbonates (HCO3)  
• Blood Urea 
• Creatinine 
Coagulation Profile 














Univariate Analysis of Independent Variables 
Clinical Characteristics Total % % Mature AVF Crude OR (95% CI) P Value 
Age       0.45  
> 50 yrs. 76.3 57.2     
≤ 50 yrs.                                                 23.7 52.1 0.814(0.477-1.389) 
Gender       0.049*  
Male 66.7 60     
Female 33.3 48 0.615 (0.379-0.998) 
Arm       0.129*  
Left 73.7 53.4     
Right 26.3 63.3 1.505(0.887-2.553) 
Fistula       0.115*  
B/C 62.7 60.1     
R/C 27 51.9 0.715 (0.423-1.208) 
BB 10.3 41.9 0.479 (0.222-1.036)   
PVD 0.001*  
Yes 16 33.3 
No 84 60.3 3.04 (1.585-5.829)   
DM  0.102* 
Yes 38 50 
No 62 59.7 1.48 (0.925-2.367)   
Univariate Analysis of Independent Variables 
Clinical Characteristics Total % % Mature AVF Crude OR (95% CI) P Value 
Smoker        0.49 
No; 86.3 55.2 0.789 (0.402-1.547) 
Yes 13.7 61     
HTN       0.406  
No 22 51.5 0.793 (0.458-1.371) 
Yes 78 57.3     
Dialysis       0.513  
No 62.7 57.4 1.17 (0.731-1.873) 
Yes 37.3 53.6     
K       0.948  
Abnormal 45.7 55.8 1.015 (0.642-1.605) 
Normal 54.3 56.2     
Na        0.439 
Abnormal 14.7 61.4 1.295 (0.673-2.494) 
Normal 85.3 55.1     
Ca 0.525  
> 2.5 13 51.3 0.804(0.41-1.577)   
≤ 2.5 87 56.7 
Univariate Analysis of Independent Variables 
Clinical Characteristics Total % % Mature AVF Crude OR (95% CI) P Value 
HCO3 0.743  
>23 55 55.2 0.926 (0.586-1.465)   
≤ 23 45 57 
Creatinine       0.676  
≤ 120 1 33.3 0.37 (0.033-4.182)   
>120 ≤400 54.3 55.2 0.913(0.576-1.447) 
>400 44.7 57.5     
Urea       0.949  
≤ 6.6 15.7 57.4 1.09 (0.73-2.073)   
>6.6-≤15 18.7 57.1 1.076 (0.591-1.960) 
>15 65.7 55.3     
eGFR 0.459  
>15 35.4 52.9 0.834 (0.516-1.349)   
≤15 64.6 57.4 
SBP 0.101*  
>130 47 48.4 1.468 (0.927-2.325)   
≤130 53 51.6 
DBP  0.786 
>85 9.3 53.6 0.897 (0.411-1.958)   
≤85 90.7 56.3 
Univariate Analysis of Independent Variables 
Clinical Characteristics Total % % Mature AVF Crude OR (95% CI) P Value 
BMI         
≤30 73.3 55     
>30 26.7 58.8 1.165 (0.694-1.957) 0.563 
PT         
≤ 13.4 86.6 56.9     
> 13.5 13.4 50 0.757 (0.389-1.474) 0.413 
INR         
≤ 1.2 88 57.6     
> 1.2 12 44.4 0.589 (0.292-1.189) 0.140* 
TC         
≤ 5 76 57.9     
>5 24 50 1.294 (0.804-2.084) 0.24* 
TG         
≤ 2.1 63.3 53.7     
> 2.1 36.7 60 0.773 (0.48-1.244) 0.289 
HDL         
≤ 1.1 51 55.6     
> 1.1 49 56.5 1.037 (0.658-1.637) 0.874 
Vein Size         
≤2.5 12.6 26.3     
>2.5 87.4 60.3 4.254 (1.983-9.126) 0.00* 
Multivariable Predictors of AVF Maturation 
 
































Total score range from -2.5 to +4 
Clinically user friendly predictive model 
-log odds of failure of fistula maturation [log/ (1/1- P)] = -1.82 + (-0.666 × 
Gender) + (1.144 × PVD) + (1.511 × Vein size) 
 Hosmer and Lemeshow Test 
Predictive 
Variables 
Beta Coefficient Error of 
significance 
Z Score Adjusted Score 
Gender -0.666 0.261 -2.55 -2.5 
PVD 1.144 0.345 3.316 +3 
Vein Size 1.511 0.402 3.76 +4 
Step Chi-square df Sig. 
1 1.045 3 .790 




0.677 85.7% 40.2% 64.5% 68.8% 
ROC Area 
The area under the ROC is 0.677, which is indicating 68% ability to discriminate 
between patients with fistula maturation. 
Conclusion 
• Gender, PVD and vein size are useful predictors of 
arteriovenous fistula maturation. 
 
• The clinical significance of these risk categories in the 
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